Belite Bio, Inc
BLTE
Rang în acțiuni
#3049
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Preț acțiune
$148.24
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$5.97B
Schimbare (1 zi)
3.82%
Schimbare (1 an)
64.04%
Țară
US
Tranzacționează Belite Bio, Inc (BLTE)
Categorie
Healthcare
Raport P/B pentru Belite Bio, Inc (BLTE)
Raport P/B la data de October 2026 TTM: 7.90
Conform celor mai recente rapoarte financiare și prețului acțiunilor Belite Bio, Inc, raportul P/B actual (TTM) este 7.90. La sfârșitul anului 2023, compania avea un P/B de 13.45.
Istoricul raportului P/B pentru Belite Bio, Inc din 2020 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 7.90 | -40.18% |
| 2024 | 13.21 | -1.78% |
| 2023 | 13.45 | -7.28% |
| 2022 | 14.51 | -185.83% |
| 2021 | -16.91 | 22.03% |
| 2020 | -13.85 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -20.89% |
US
|
|
| 13.2547 | 67.75% |
US
|
|
| 4.208 | -46.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -21.76% |
NL
|
